MARKET

XLRN

XLRN

Acceleron
NASDAQ

Real-time Quotes | Nasdaq Last Sale

127.71
-1.00
-0.78%
Opening 13:03 06/16 EDT
OPEN
128.84
PREV CLOSE
128.71
HIGH
129.87
LOW
127.44
VOLUME
54.48K
TURNOVER
--
52 WEEK HIGH
146.15
52 WEEK LOW
85.58
MARKET CAP
7.75B
P/E (TTM)
-42.5672
1D
5D
1M
3M
1Y
5Y
Bristol Myers, Acceleron's Reblozyl shows encouraging action in adults with beta thalassemia
Bristol Myers Squibb (BMY) and Acceleron Pharma (XLRN) announce the first data from Phase 2 BEYOND study evaluating Reblozyl (luspatercept-aamt) plus best supportive care in adult patients with non-transfusion dependent ((NTD)) beta thalassemia.Results
Seekingalpha · 5d ago
BRIEF-Bristol Myers & Acceleron Present First Results From Phase 2 Beyond Study Of Reblozyl
reuters.com · 5d ago
Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
PRINCETON, N.J. & CAMBRIDGE, Mass., Jun 11, 2021--BMS & Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
Business Wire · 5d ago
Insider Trends: Insider at Acceleron Pharma Sells for Tax Adds to 90-Day Selling Trend
MT Newswires · 06/08 18:50
Acceleron to Host Virtual Research and Development (R&D) Day on June 22, 2021
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it will host a Virtual R&D Day for analys...
Business Wire · 06/08 11:00
Darwin Global Management, Ltd. Buys BridgeBio Pharma Inc, Acceleron Pharma Inc, Fate ...
GuruFocus News · 05/19 19:38
Ongoing Treatment With Acceleron's Sotatercept Continue To Show Benefit In PAH Patients
Benzinga · 05/19 19:15
Acceleron reports preliminary sotatercept data from mid-stage SPECTRA trial in PAH
Acceleron Pharma (XLRN) presents preliminary interim data from the SPECTRA Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension ((PAH)).The trial shows that sotatercept-treated patients  experienced improvements in
Seekingalpha · 05/19 13:08
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XLRN. Analyze the recent business situations of Acceleron through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XLRN stock price target is 153.77 with a high estimate of 200.00 and a low estimate of 111.00.
EPS
Institutional Holdings
Institutions: 352
Institutional Holdings: 56.65M
% Owned: 93.33%
Shares Outstanding: 60.70M
TypeInstitutionsShares
Increased
81
3.46M
New
36
778.86K
Decreased
89
3.46M
Sold Out
29
344.17K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.52%
Pharmaceuticals & Medical Research
-0.07%
Key Executives
Non-Executive Chairman/Independent Director
Francois Nader
President/Chief Executive Officer/Director
Habib Dable
Chief Financial Officer/Senior Vice President/Treasurer
Kevin McLaughlin
Chief Financial Officer/Senior Vice President/Treasurer
Kevin Mclaughlin
Executive Vice President
Jay Backstrom
Executive Vice President
Sujay Kango
Senior Vice President/General Counsel/Secretary
Adam Veness
Senior Vice President
Christopher R. Rovaldi
Independent Director
Laura Hamill
Independent Director
Christopher Hite
Independent Director
Terrence Kearney
Independent Director
Kemal Malik
Independent Director
Thomas McCourt
Independent Director
Karen Smith
Independent Director
Joseph Zakrzewski
No Data
About XLRN
Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.

Webull offers kinds of Acceleron Pharma Inc stock information, including NASDAQ:XLRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XLRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XLRN stock methods without spending real money on the virtual paper trading platform.